Argos Therapeutics, Inc. (ARGS) Posts Q2 Loss of 61c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Argos Therapeutics Reports Second Quarter 2014 Financial Results and Operational Highlights
August 13, 2014 4:05 PM EDTDURHAM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, today reported financial results for the second quarter ended June 30, 2014, and provided an update on the Company's clinical programs.
"We continue to be pleased with the progress we are making in our ADAPT phase 3 trial of AGS-003 in metastatic renal cell carcinoma (mRCC), as we now have collected tumors for screening for eligibility... More
